The effects of a new aminodisphosphonate, aminohydroxybutylidene-disphosphonate (AHBuDP) in a 61 years old woman, affected by multiple myeloma with osteolytic lesions and hypercalcemia, are described. AHBuDP infusions induced a fast decrease in calcium levels, improvement of renal function and a relief in bone pain. Serum calcium remained normal up to four weeks after stopping AHBuDP, when the patient died of pneumonia.
|Number of pages||2|
|Journal||Medicina - Rivista della Enciclopedia Medica Italiana|
|Publication status||Published - 1988|
ASJC Scopus subject areas